When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
NVCR - Novocure enrolls last patient in Hepanova combo trial in advanced liver cancer
NovoCure Limited
The last patient has been enrolled in Novocure's (NASDAQ:NVCR) HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. Final data collection will occur in six months.
More news on: NovoCure Limited, Healthcare stocks news,